Summit Therapeutics (SMMT) Non-Current Receivables (2021 - 2024)
Summit Therapeutics filings provide 4 years of Non-Current Receivables readings, the most recent being $698000.0 for Q4 2024.
- Quarterly Non-Current Receivables fell 27.22% to $698000.0 in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $698000.0 through Dec 2024, down 27.22% year-over-year, with the annual reading at $698000.0 for FY2024, 27.22% down from the prior year.
- Non-Current Receivables hit $698000.0 in Q4 2024 for Summit Therapeutics, up from $467000.0 in the prior quarter.
- Across five years, Non-Current Receivables topped out at $11.3 million in Q3 2021 and bottomed at $212000.0 in Q1 2024.
- Average Non-Current Receivables over 4 years is $2.4 million, with a median of $747000.0 recorded in 2023.
- The largest annual shift saw Non-Current Receivables plummeted 77.92% in 2023 before it fell 27.22% in 2024.
- Summit Therapeutics' Non-Current Receivables stood at $11.3 million in 2021, then tumbled by 70.79% to $3.3 million in 2022, then tumbled by 70.95% to $959000.0 in 2023, then fell by 27.22% to $698000.0 in 2024.
- Per Business Quant, the three most recent readings for SMMT's Non-Current Receivables are $698000.0 (Q4 2024), $467000.0 (Q3 2024), and $364000.0 (Q2 2024).